Related Experiment Videos
Evaluating drug effects on children's cognitive functioning
Insights
This study found that bupropion (Wellbutrin) and alprazolam (Xanax) did not negatively impact cognitive skills in children with psychiatric disorders. Cognitive testing showed no adverse effects at effective doses.
Area of Science:
- Child Psychiatry
- Neuroscience
- Pharmacology
Background:
- Assessing medication effects on cognitive processing is crucial in child psychiatry.
- Cognitive skills are vital for academic success in children.
Purpose of the Study:
- To evaluate the impact of bupropion and alprazolam on cognitive functions in pediatric patients.
- To determine if these medications cause adverse cognitive effects relevant to classroom performance.
Main Methods:
- Utilized a cognitive test battery to monitor cognitive processing.
- Conducted open clinical trials with child psychiatry patients receiving bupropion or alprazolam.
- Compared medication effects against placebo where applicable.
Main Results:
- Bupropion showed no significant negative effects on individual cognitive tests compared to placebo.
- Alprazolam group performance was variable, with no significant changes on individual tests.
- No cognitive deterioration was observed with either medication at therapeutic doses.
Conclusions:
- Bupropion, an antidepressant, and alprazolam, an anxiolytic, appear safe for cognitive function in children at therapeutic doses.
- The cognitive test battery is a useful tool for monitoring medication effects in pediatric psychopharmacology.
Abstract:
In our studies of drug therapy in child psychiatry disorders, we have been using a battery of tests to monitor any effects of medication on the various components of cognitive processing. Our intention was to measure skills required by the children for successful classroom performance. We have used this test battery approach in open clinical trials of bupropion (Wellbutrin) and of alprazolam (Xanax) with child psychiatry patients. On no single test was the effect of bupropion vs placebo significant; however, there was no indication of any cognitive deterioration with bupropion. Group performance with alprazolam was more variable, and again no individual test showed significant changes with medication. These initial applications of the cognitive battery indicate that bupropion, a new antidepressant and alprazolam, an anxiolytic have no adverse effects on cognition at therapeutically effective doses.